✦ LIBER ✦

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma

✍ Scribed by Santoro, A; Pressiani, T; Citterio, G; Rossoni, G; Donadoni, G; Pozzi, F; Rimassa, L; Personeni, N; Bozzarelli, S; Rossoni, G

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6617 Phase II study of NGR-hTNF, a selec

✍ Santoro, A.; Citterio, G.; Pressiani, T.; Gregorc, V.; Rimassa, L.; De Braud, F. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

9011 NGR-hTNF, a vascular targeting agen

✍ Gregorc, V.; Ceresoli, G.L.; Zucali, P.A.; De Braud, F.G.; Bajetta, E.; Santoro, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Phase Ib study of NGR–hTNF, a selective

✍ Gregorc, V; Santoro, A; Bennicelli, E; Punt, C J A; Citterio, G; Timmer-Bonte, J 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 216 KB

Phase II study of NGR-hTNF, a selective

✍ Armando Santoro; Lorenza Rimassa; Alberto F. Sobrero; Giovanni Citterio; Frances 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 206 KB

Activity of weekly paclitaxel in patient

✍ Maurie Markman; Jeffrey Fowler 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 80 KB

The use of single-agent sorafenib in the

✍ Joanne Chiu; Yuen Fong Tang; Tzy-Jyun Yao; Ashley Wong; Hilda Wong; Roland Leung 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 792 KB